THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA
A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS
PLC
("BiVictriX" or "the
Company")
Director
Dealing
Alderley Park, 2 September 2024
BiVictriX Therapeutics plc (AIM: BVX), a drug
discovery and development company applying an innovative,
proprietary approach to develop a new class of highly selective,
next generation cancer therapeutics, bispecific antibody drug
conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst
reducing treatment-related toxicities, announces the following
dealing in the Company's ordinary shares of 1 pence each
("Ordinary Shares").
On 30 August 2024, Mr Robert
Hawkins, a Non-Executive Director, carried out a 'Bed and ISA'
transfer of20,000 Ordinary Shares from his ISA account into a share
dealing account (the "Transfer"). The shares were sold for 7.26
pence per Ordinary Shares and immediately repurchased at 7.92 pence
per Ordinary Share.
Following the Transfer, Robert
Hawkins remains beneficially interested in 325,000 Ordinary Shares
which equates to 0.39 per cent. of the Company's total issued share
capital.
ENDS
|
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive
Officer
Michael Kauffman, Non-Executive
Chairman
|
Email: info@bivictrix.com
|
|
SP
Angel Corporate Finance LLP (NOMAD and Broker)
David Hignell, Caroline Rowe (Corporate
Finance)
Vadim Alexandre, Rob Rees (Sales and Broking)
|
Tel: +44
(0) 20 3470 0470
|
|
Panmure Liberum Limited (Joint Broker)
Emma Earl, Freddy Crossley, Mark Rogers, Rupert
Dearden
|
Tel: +44
(0) 20 3100 2000
|
|
ICR
Consilium
Namrata Taak, Lucy Featherstone, Max
Bennett, Emmalee Hoppe
|
Tel: +44
(0) 20 3709 5700
Email: Bivictrix@consilium-comms.com
|
About BiVictriX Therapeutics plc
BiVictriX (AIM: BVX) is an emerging
biotechnology company leveraging clinical experience and its
proprietary discovery engine to advance a new class of highly
cancer-selective, next-generation precision cancer therapies in one
of the fastest-growing markets in oncology. BiVictriX's
first-in-class Bi-Cygni® Antibody Drug Conjugates ("ADCs") combine
superior efficacy with substantially improved
cancer-selectivity and safety to provide opportunities for
prolonged dosing and greater efficacy in the clinic. The Company is
advancing its pipeline to deliver the future of cancer care across
a broad range of haematological and solid cancer indications in
areas of high unmet medical need.
Find out more
at www.bivictrix.com and
connect with us on LinkedIn and
Twitter @BiVictriX.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Robert Hawkins
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
BiVictriX Therapeutics
plc
|
|
b)
|
LEI
|
213800ZI85IZNA6N3L53
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 1 pence
each
GB00BNXH3K91
|
|
Identification code
|
|
|
b)
|
Nature of the transaction
|
(i)
Sale of 20,000 Ordinary Shares from ISA account
(ii)
Purchase of 20,000 Ordinary Shares from share dealing
account
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
(i)
7.26 pence
(ii)
7.92 pence
|
20,000
20,000
|
|
|
d)
|
Aggregated information:
- Aggregated volume
- Price
|
N/A single
transaction
|
|
e)
|
Date of the transaction
|
30 August 2024
|
|
f)
|
Place of the transaction
|
AIM, London Stock Exchange
|
